Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: February 4, 2009

ABRAXANE Now Available in Germany and the United Kingdom

(Nanowerk News) Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced the launch in Germany of ABRAXANE, 5 mg/ml powder for suspension for infusion (paclitaxel).
"ABRAXANE is an ideal treatment for breast cancer patients because of its superior clinical benefits and improved tolerability profile compared to solvent-based paclitaxel,” said Prof. Dr. med. Gunter von Minckwitz, Managing Director, German Breast Group Forschungs GmbH, Neu-Isenburg, Germany. “Additionally, ABRAXANE does not require premedication and can be administered in 30 minutes versus over 3 hours for solvent-based paclitaxel chemotherapy. ABRAXANE should therefore be considered as a new and attractive option for oncologists treating metastatic breast cancer in patients who have failed first-line therapy in Germany.”
In the EU, ABRAXANE is indicated for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
ABRAXANE is a unique formulation of paclitaxel with a mean particle size of approximately 130 nanometers, that uses the natural properties of a human protein, albumin, to deliver the drug more effectively to tumors. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses, resulting in higher concentrations of the drug at the tumor site and higher efficacy compared to solvent-based paclitaxel. Clinical trials have demonstrated that the tumor response rate was nearly double for patients who received ABRAXANE compared to those who received solvent-based paclitaxel. Of great significance, patients treated with ABRAXANE experienced a significant improvement in progression-free survival and prolonged time to tumor progression compared to patients treated with solvent-based paclitaxel (Gradishar 2005).
Toxic solvents, such as Cremophor® EL, involved in the delivery of currently approved paclitaxel on the market may be the cause of the significant treatment-related side effects, including anaphylaxis and allergic reactions. Patients receiving ABRAXANE, a solvent free paclitaxel, do not require premedication before treatment to avoid these reactions related to toxic solvents.
“The launch of ABRAXANE in Germany is a significant step in our goal to provide patients across Europe with a new option for the treatment of metastatic breast cancer,” said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience. “This marks an important milestone in building a truly global presence for Abraxis BioScience as we continue to seek approvals for new indications for ABRAXANE and continue to develop advanced medicines in our pipeline.”
“In Europe, we have assembled a solid group of seasoned marketing, regulatory and product support professionals to market this new treatment for women with metastatic breast cancer,” said Jean-François Gimonet, M.D., Vice President, European Operations of Abraxis BioScience. “The introduction of ABRAXANE in Germany greatly advances our organization across Europe and further advances Abraxis BioScience towards its goal of becoming an industry leader in the European Union.”
ABRAXANE is available through hospitals in Germany. Following the launches in the United Kingdom and Germany, ABRAXANE will be launched in additional nations in Europe on a country by country basis in 2009.
ABRAXANE has now been approved for marketing in 36 countries across Europe, North America, Asia and Australia. In addition to Germany and the United Kingdom, ABRAXANE is commercially available in the United States and Canada and in India in collaboration with Biocon Limited. In 2009, ABRAXANE is anticipated to launch in Australia in collaboration with Specialised Therapeutics Australia Pty Ltd; in the United Arab Emirates with partner Neobiocon; and in Korea with partner Green Cross Corporation. Additionally, marketing approval for ABRAXANE has been received in China with an anticipated launch in 2009. ABRAXANE is currently under active review in Japan and Russia.
Source: Abraxis BioScience (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
These articles might interest you as well: